• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Scientific Publications by FDA Staff

  • Print
  • Share
  • E-mail
-

Search Publications



Fields



Centers











Starting Date


Ending Date


Order by

Entry Details

Mol Cancer Ther 2016 Mar;15(3):480-90

Ado-trastuzumab emtansine targets hepatocytes via human epidermal growth factor receptor 2 to induce hepatotoxicity.

Yan H, Endo Y, Shen Y, Rotstein D, Dokmanovic M, Mohan N, Mukhopadhyay P, Gao B, Pacher P, Wu WJ

Abstract

Ado-trastuzumab emtansine (T-DM1) is an antibody-drug conjugate (ADC) approved for the treatment of HER2-positive metastatic breast cancer. It consists of trastuzumab, a humanized monoclonal antibody directed against human epidermal growth factor receptor 2 (HER2) and a microtubule inhibitor DM1 conjugated to trastuzumab via a thioether linker. Hepatotoxicity is one of the serious adverse events associated with T-DM1 therapy. Mechanisms underlying T-DM1-induced hepatotoxicity remain elusive. Here, we use hepatocytes and mouse as models to investigate the mechanisms of T-DM1-induced hepatotoxicity. We show that T-DM1 is internalized upon binding to cell surface HER2 and is co-localized with LAMP1, resulting in DM1-associated cytotoxicity, including disorganized microtubules, nuclear fragmentation/multiple nuclei, and cell growth inhibition. We further demonstrate that T-DM1 treatment significantly increases the serum levels of aspartate aminotransferase (AST), alanine aminotransferase (ALT), lactate dehydrogenase (LDH) in mice, and induces inflammation and necrosis in liver tissues and that T-DM1-induced hepatotoxicity is dose dependent. Moreover, the gene expression of TNFalpha in liver tissues is significantly increased in mice treated with T-DM1 as compared with that treated with trastuzumab or vehicle. We propose that T-DM1-induced upregulation of TNFalpha enhances the liver injury that may be initially caused by DM1-mediated intracellular damage. Our proposal is underscored by the fact that T-DM1 induces the outer mitochondrial membrane rupture, a typical morphological change in the mitochondrial-dependent apoptosis, and mitochondrial membrane potential dysfunction. Our work provides mechanistic insights into T-DM1-induced hepatotoxicity, which may yield novel strategies to manage liver injury induced by T-DM1 or other ADCs.


Category: Journal Article
PubMed ID: #26712117 DOI: 10.1158/1535-7163.MCT-15-0580
Includes FDA Authors from Scientific Area(s): Drugs Animal and Veterinary
Entry Created: 2016-02-19 Entry Last Modified: 2016-04-30
Feedback
-
-